Clinical Trials
2
Trial Phases
1 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials
Intensive Compared With Nonintensive Chemotherapy in Treating Older Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome
- Conditions
- Myelodysplastic SyndromesMyelodysplastic/Myeloproliferative NeoplasmsLeukemia
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-12-18
- Lead Sponsor
- Leukemia Research Fund
- Target Recruit Count
- 2000
- Registration Number
- NCT00005823
- Locations
- 🇬🇧
Queen Elizabeth Hospital at University of Birmingham, Birmingham, England, United Kingdom
🇬🇧University College Hospital, London, England, United Kingdom
🇬🇧University Hospital of Wales, Cardiff, Wales, United Kingdom
Chemotherapy in Treating Patients With Newly Diagnosed Chronic Lymphocytic Leukemia
- Conditions
- Leukemia
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-12-18
- Lead Sponsor
- Leukemia Research Fund
- Registration Number
- NCT00004218
- Locations
- 🇦🇷
Hospital Italiano de Buenos Aires, Buenos Aires, Argentina
🇦🇷Hospital Alvarez, Buenos Aires, Argentina
🇭🇷University Hospital Rebro, Zagreb, Croatia
News
New Bone Marrow Test Could Double Survival Rates for Acute Myeloid Leukemia Patients
A groundbreaking UK trial has developed a highly sensitive bone marrow test that can detect returning Acute Myeloid Leukemia up to three months earlier than standard blood tests, potentially doubling survival rates for some patients.
Diabetes Drug Metformin Shows Promise in Preventing Acute Myeloid Leukemia
Cambridge researchers discover that metformin, a widely prescribed diabetes medication, may help prevent acute myeloid leukemia (AML) in high-risk individuals by targeting mutations in the DNMT3A gene.
NHS Approves Breakthrough CAR T-Cell Therapy Liso-cel for Advanced Lymphoma Patients
A groundbreaking CAR T-cell therapy, liso-cel, has been approved by NHS for treating large B-cell lymphoma patients who haven't responded to initial treatment or experienced relapse within 12 months.
Teclistamab Approved for Fourth-Line Myeloma Treatment on NHS in England and Wales
Teclistamab (Tecvayli) has been approved by NICE for fourth-line treatment of multiple myeloma in England and Wales, offering a new option for patients who have exhausted other treatments.